Zacks Investment Research cut shares of DBV Technologies S.A. (NASDAQ:DBVT) from a buy rating to a hold rating in a research report report published on Tuesday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
Several other research analysts have also issued reports on DBVT. HC Wainwright reaffirmed a buy rating and set a $50.00 target price on shares of DBV Technologies in a research report on Thursday, July 6th. Morgan Stanley reaffirmed an overweight rating on shares of DBV Technologies in a research report on Monday, July 10th. ValuEngine raised DBV Technologies from a sell rating to a hold rating in a research report on Thursday, July 13th. BidaskClub raised DBV Technologies from a hold rating to a buy rating in a research report on Tuesday, July 25th. Finally, Leerink Swann upped their target price on DBV Technologies from $54.00 to $60.00 and gave the company an outperform rating in a research report on Friday, August 25th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. DBV Technologies currently has a consensus rating of Buy and a consensus price target of $49.63.
Shares of DBV Technologies (NASDAQ:DBVT) traded down $0.21 during trading hours on Tuesday, reaching $23.22. The company had a trading volume of 158,402 shares, compared to its average volume of 1,202,894.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Lowers DBV Technologies S.A. (DBVT) to Hold” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.com-unik.info/2017/11/03/zacks-investment-research-lowers-dbv-technologies-s-a-dbvt-to-hold.html.
A number of institutional investors have recently bought and sold shares of the business. Alps Advisors Inc. grew its stake in DBV Technologies by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 47,477 shares of the company’s stock valued at $2,015,000 after purchasing an additional 3,964 shares during the last quarter. Sabby Management LLC purchased a new stake in DBV Technologies during the 2nd quarter valued at about $1,339,000. Dynamic Technology Lab Private Ltd purchased a new stake in DBV Technologies during the 2nd quarter valued at about $222,000. Janus Henderson Group PLC purchased a new stake in DBV Technologies during the 2nd quarter valued at about $90,724,000. Finally, Sectoral Asset Management Inc grew its stake in DBV Technologies by 34.2% during the 2nd quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock valued at $6,398,000 after purchasing an additional 45,653 shares during the last quarter. Institutional investors and hedge funds own 45.51% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about DBV Technologies S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DBV Technologies S.A. and related companies.